Eton Pharmaceuticals (ETON) Q4 2025 earnings summary

Executive summary

• Achieved transformational growth in 2025, more than doubling revenue year-over-year to $80 million, driven by launches of Increlex, Galzin, KHINDIVI, and ALKINDI SPRINKLE.

• Successfully launched DESMODA, the only FDA-approved oral liquid desmopressin, addressing a significant unmet need in central diabetes insipidus.

• Acquired HEMANGEOL, the only FDA-approved treatment for infantile hemangiomas, with plans for a value-creating relaunch and distribution optimization; expected to be accretive to 2026 earnings.

• Set new long-term goals: largest rare disease portfolio in the U.S., $200M revenue run rate by 2027, 50% adjusted EBITDA margin by 2028, and $500M revenue by 2030.

• Management expects 2026 revenue to exceed $110 million with Adjusted EBITDA margin over 30%.

Financial highlights

• Q4 2025 revenue was $21.3M, up 83% year-over-year; full-year revenue totaled $80M, more than doubling from 2024.

• Adjusted EBITDA margin improved to 29% in Q4 2025 from 18% in Q4 2024.

• Adjusted gross profit margin rose to 73% in Q4 2025 from 59% in the prior year.

• GAAP net income for Q4 was $1.5M ($0.06 basic, $0.05 diluted per share); non-GAAP net income was $5.4M ($0.19 per diluted share).

• Ended Q4 with $25.9M in cash; Q4 operating cash outflow was $11.6M due to Medicaid rebates, FDA fees, and inventory payments.

Outlook and guidance

• 2026 revenue expected to exceed $110M with adjusted EBITDA margin above 30%.

• Targeting $200M revenue run rate by end of 2027, driven by organic growth and potential acquisitions.

• DESMODA peak sales guidance remains $30M–$50M, with potential upside from adult market expansion.

• Full-year adjusted gross margin expected above 70%, ramping to 75–80% in coming years.

• Multiple clinical studies planned or underway for INCRELEX, KHINDIVI, ET-700, and AMGLIDIA.